The pandemic pipeline

Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics. Companies are doing their best to accelerate experi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2020-05, Vol.38 (5), p.523-532
1. Verfasser:	Hodgson, John
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - classification Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Coronavirus Infections - drug therapy Coronavirus Infections - prevention & control Coronaviruses COVID-19 Drug Development - economics Drug Repositioning Drugs Humans News Feature Pandemics Pandemics - prevention & control Pneumonia, Viral - drug therapy Pneumonia, Viral - prevention & control Time Factors Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics. Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/d41587-020-00005-z